Abstract
Diethylstilbestrol (DES), a powerful synthetic estrogen introduced in 1938, was prescribed to prevent pregnancy complications, but was later shown to have a series of adverse side-effects in the offspring, including cancer of the vagina. Recent evidence indicates that in utero exposure to DES is also linked to breast cancer in women over the age of 40 years. This evidence provides support to the hypothesis that in utero exposures may affect breast cancer risk in adult life.
This is a preview of subscription content, access via your institution.
References
Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1509–14.
Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med. 2011;365:1304–14.
Greenberg ER, Barnes AB, Resseguie L, Barrett JA, Burnside S, Lanza LL, et al. Breast cancer in mothers given diethylstilbestrol in pregnancy. N Engl J Med. 1984;311:1393–8.
Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878–81.
Weiss HA, Potischman NA, Brinton LA, Brogan D, Coates RJ, Gammon MD, et al. Prenatal and perinatal risk factors for breast cancer in young women. Epidemiology. 1997;8:181–7.
Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH, Mittendorf R, et al. Cancer risk in women exposed to diethylstilbestrol in utero. JAMA. 1998;280:630–4.
Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: preliminary results (United States). Cancer Causes Control. 2002;13:753–8.
Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet. 1990;335(8695):939–40.
Lagiou P, Adami HO, Trichopoulos D. Causality in cancer epidemiology. Eur J Epidemiol. 2005;20:565–74.
Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA. Cancer risk in DES daughters. Cancer Causes Control. 2010;21:999–1007.
Rothman KJ. Modern epidemiology. Boston: Little Brown; 1986. p. 19.
Trichopoulos D, Adami HO, Ekbom A, Hsieh CC, Lagiou P. Early life events and conditions and breast cancer risk: from epidemiology to etiology. Int J Cancer. 2008;122:481–5.
Smith OW, Smith GV, Hurwitz D. Increased excretion of pregnanediol in pregnancy from diethylstilbestrol with special reference to the prevention of late pregnancy accidents. Am J Obstet Gynecol. 1946;51:411–5.
Acknowledgments
This work was supported by Karolinska Institutet, Distinguished Professor Award (grant number Dnr: 2368/10-221).
Conflict of interest
Dr. Adami has been retained as a consultant in litigation on behalf of DES daughters claiming breast cancer injury due to DES exposure.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Adami, HO., Lagiou, P. & Trichopoulos, D. Breast cancer following diethylstilbestrol exposure in utero: insights from a tragedy. Eur J Epidemiol 27, 1–3 (2012). https://doi.org/10.1007/s10654-012-9655-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-012-9655-0
Keywords
- Diethylstilbestrol
- DES
- Estrogens
- In utero
- Breast cancer